Celgene Corporation CELG
-
IPO Preview: Bluebird Bio
By IPOdesktop : Based in Cambridge, MA, bluebird bio ( BLUE ) scheduled a $75 million IPO with a market capitalization of $314 million at a price range mid-point of $15, for Wednesday, June 19, 2013. Four other new IPOs are scheduled for the week of June 17th. The full IPO calendar is here . S-1 ...
-
Bristol-Myers Squibb's (BMY) and AbbVie's (ABBV) Elotuzumab helped patients with previously-treated multiple myeloma live for a median 33 months without the blood cancer getting worse in a Phase II ...
… live for a median 33 months without the blood cancer getting worse in a Phase II trial. The drug was given with Celgene's ( CELG ) Revlimid and the steroid dexamethasone. Elotuzumab is also being tested in two Phase III trials for multiple myeloma. ( PR …
-
Cramer's Mad Money - The Kids' Portfolio (6/13/13)
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday June 13. The Kids' Portfolio: Disney ( DIS ), Nike ( NKE ), Gap ( GPS ), Hasbro ( HAS ), Whole Foods ( WFM ), Apple ( AAPL ), Google ( GOOG ). Other stocks mentioned: Lockheed ...
-
Novartis: Drug Pipeline And New Drug Applications
By Bio Vantage : In Part 1 of our recent Novartis ( NVS ) report ( Novartis: 5-Year Revenue Outlook ), we discussed that the declining drug sales for key products (e.g. Diovan) would impact its revenues for 2013, whereas the newly approved drugs would eventually contribute to future revenue growth.
-
Celgene's ([[ CELG ]] -0.1%) Apremilast drug significantly improved the signs and symptoms of patients with psoriatic arthritis in the company's "Palace 3" Phase III study. The results come a day after ...
Celgene's ( CELG -0.1% ) Apremilast drug significantly improved the signs and symptoms of patients with psoriatic arthritis in the company …
-
Warning: This Might Be The Most Overvalued Sector In The Market
By StreetAuthority : By David Sterman When it comes to assessing the outlook for drugmakers, investors really only care about the pipeline of new drugs. After all, existing drugs eventually lose patent protection, and when that happens, a large hole in the income statement can appear. Just a few ...
-
Moody's raises Celgene's ( CELG ) outlook to Positive from Stable citing the "expanding use of Revlimid" (I, II) and "pending approvals of Apremilast in psoriatic arthritis and Abraxane in pancreatic ...
Moody's raises Celgene's ( CELG ) outlook to Positive from Stable citing the "expanding use of Revlimid" ( I , II ) and "pending approvals of Apremilast in …
-
Clovis / CO-1686: Value, Derived From Data, Supports The Valuation
… specifically, the acquisition of CO-1686 through an interrupted partnership with Avila Therapeutics (due to Celgene's ( CELG ) acquisition) and the licensing deal which gave Clovis control of Pfizer's ( PFE ) old PARP inhibitor Rucaparib (aka PF …
-
Biotech startup Agios Pharmaceuticals has filed to raise $86M in an IPO. The company has raised over a quarter of a billion dollars from VC firms and Celgene ( CELG ), which has invested $37.5M and ...
… Pharmaceuticals has filed to raise $86M in an IPO. The company has raised over a quarter of a billion dollars from VC firms and Celgene ( CELG ), which has invested $37.5M and made $141.2M in collaboration payments. Celgene has also committed to buying stock in …
-
Celgene Moves Fast And Early In Expanding Its Pipeline
By Peter Geschek : Celgene's ( CELG ) stated goal is to double its sales by 2017 and in order to achieve that, it pursues a three-way strategy: expand Revlimid …